Recently, the monoclonal antibody anti-BCMA conjugated with the MonoMethyl Auristatin F, GSK2857916 (Belantamab Mafodotin) [68], has shown promise when tested in different studies, either as a single agent or in combination with other drugs, in the therapy of heavily pre-treated MM patients [69,70]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.